Abstract
Background: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the development of resistance to monotherapy is an issue. The anti-angiogenic properties of pazopanib could overcome crizotinib drug resistance. Additionally, the anti-angiogenic properties of crizotinib could augment the clinical efficacy of pazopanib. Methods: We evaluated the safety and responses in patients with advanced solid tumors treated with crizotinib and pazopanib. Results: Eighty-two patients (median age 53 years, range 18–78 years) were enrolled. The median number of prior systemic therapies was 3 (range, 0–8). We were able to dose escalate to dose level 8 (crizotinib 250 mg twice daily and pazopanib 800 mg daily) with no MTD identified. Grade 3 or 4 toxicities were seen in 32% of patients with the highest prevalence being fatigue (n=9, 11%), diarrhea (n=6, 7%), vomiting (n=3, 4%), anemia (n=2, 2%) and ALT increased (n=2, 2%). Of the 82 patients, 61 (74%) had measurable disease by RECISTv1.1 and reached first restaging (6 weeks). Partial response (PR) was observed in 6/61 (10%) patients, and stable disease (SD) lasting ≥6 months was observed in 10/61 patients (16%) (total = 16/61 (26%) of patients with SD ≥6 months/PR). Conclusion: Dose level 6 (crizotinib 200 mg twice daily and pazopanib 600 mg daily) was the most tolerable dosing of the combination and can be used in future studies. We also observed moderate clinical activity in patients with advanced solid tumors that had received numerous prior therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 3037-3049 |
Number of pages | 13 |
Journal | OncoTargets and Therapy |
Volume | 14 |
DOIs | |
State | Published - 2021 |
Keywords
- ALK/ROS1
- Crizotinib
- MET
- Pazopanib
- VEGF
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
MD Anderson CCSG core facilities
- Clinical and Translational Research Center
Fingerprint
Dive into the research topics of 'A phase i trial of the met/alk/ros1 inhibitor crizotinib combined with the vegf inhibitor pazopanib in patients with advanced solid malignancies'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: OncoTargets and Therapy, Vol. 14, 2021, p. 3037-3049.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A phase i trial of the met/alk/ros1 inhibitor crizotinib combined with the vegf inhibitor pazopanib in patients with advanced solid malignancies
AU - Piha-Paul, Sarina A.
AU - Dumbrava, Ecaterina E.
AU - Nair, Binoj C.
AU - Xiong, Wendy
AU - Xu, Li
AU - Mostorino, Rosa
AU - Subbiah, Vivek
AU - Tannir, Nizar
AU - Fu, Siqing
AU - Naing, Aung
AU - Janku, Filip
AU - Karp, Daniel D.
AU - Patel, Shreyaskumar
AU - Daw, Najat C.
AU - Hong, David
AU - Meric-Bernstam, Funda
AU - Zinner, Ralph
N1 - Funding Information: from Jazz Pharmaceuticals, personal fees from PureT ech Health, Bio-Rad, Biocartis, outside the submitted work. Dr Shreyaskumar Patel reports personal fees from DAiichi SAnkyo, personal fees from Deciphera, consultant fees from Epizyme, Dova and Bayer , grants from Blueprint Medicines, Clinical T rial fees from Hutchison Medipharma, outside the submitted work. Dr David Hong reports grants from AbbV ie, grants, Grant/Research Support & Consulting/Advisory Role from Adaptimmune, grants from Aldi-Norte, grants, Grant/ Research Support & Consulting/Advisory Role from Amgen, grants from Astra-Zeneca, grants, Grant/Research Support, Consulting/Advisory Role, T ravel, Accommodations, Expenses from Bayer , grants from BMS, grants from Daiichi-Sankyo, grants from Eisai, grants from Fate Therapeutics, grants, Grant/Research Support & Consulting/Advisory Role from Genentech, grants from Genmab, grants from Ignyta, grants, Grant/Research Support & Consulting/Advisory Role from Infinity , grants from Kite, grants from Kyowa, grants from Lily , grants, Grant/Research Support & T ravel, Accommodations, Expenses from LOXO, grants from Merck, grants from MedImmune, grants from Mirati, grants, Grant/Research Support & T ravel, Accommodations, Expenses from miRNA, grants from Molecular T emplates, grants from Mologen, grants from NCI-CTEP , grants from Novartis, grants, Grant/Research Support & Consulting/Advisory Role from Numab, grants, Grant/Research Support & Consulting/Advisory Role from Pfizer , grants, Grant/ Research Support & Consulting/Advisory Role from Seattle Genetics, Grant/Research Support & Consulting/ Advisory Role from T akeda, grants from T urning Point Therapeutics, V erstatem, Consulting/Advisory Role from Alpha Insights, Acuta, Axion, Baxter , Boxer Capital, COG, ECOR1, Expert Connect, GLG, Group H, Guidepoint, H.C. W ainwright, Janssen, Merrimack, Medscape, NTRK Connect, Prime Oncology , Slingshot, T rieza Therapeutics, W ebMD, T ravel, Accommodations, Expenses from ASCO, AACR, SITC, Advisor from Molecular Match, Founder from OncoResponse, Advisor from Presagia, outside the submitted work. Dr Funda Meric-Bernstam reports personal fees from Aduro BioT ech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F . Hoffman-La Roche Ltd., Genentech Inc., IBM W atson, Jackson Laboratory , Kolon Life Science, OrigiMed, P ACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., T yra Biosciences, Xencor , Zymeworks, Immunomedics, Advisory Committee from Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Silverback Therapeutics, Spectrum Pharmaceuticals Zentalis, grants from Aileron Therapeutics, Sponsored Research from AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals, Novartis, Puma Biotechnology Inc., T aiho Pharmaceutical Co., personal fees from Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey , Beth Israel Deaconess Medical Center , outside the submitted work. The authors report no other conflicts of interest in this work. Funding Information: Dr Sarina A. Piha-Paul reports Clinical T rial Research Support (Received through the institution) from AbbV ie, Inc., ABM Therapeutics, Inc., Acepodia, Inc., Alkermes, Aminex Therapeutics, Amphivena Therapeutics, Inc., BioMarin Pharmaceutical, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Cerulean Pharma, Inc., Chugai Pharmaceutical Co., Ltd., Curis, Inc., Daiichi Sankyo, Inc., Eli Lilly , ENB Therapeutics, Five Prime Therapeutics, Gene Quantum, Genmab A/S, Glaxo SmithKline, Helix BioPharma Corp., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd., MedImmune, LLC., Medivation, Inc., Merck Sharp and Dohme Corp., Novartis Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer , Principia Biopharma, Inc., Puma Biotechnology , Inc., Rapt Therapeutics, Inc., Seattle Genetics, Silverback Therapeutics, T aiho Oncology , T esaro, Inc., T ransThera Bio, Core Grant (CCSG Shared Resources Clinical T rial Research Support (Received through the institution)) from NCI/NIH P30CA016672, outside the submitted work. Dr V ivek Subbiah reports Research funding/Grant support for clinical trials (to institution): Novartis, Bayer , Berghealth, Incyte, Fujifilm, Pharmamar , D3, Pfizer , Multivir , Amgen, AbbV ie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Loxo Oncology , MedImmune, Altum, Dragonfly Therapeutics, T akeda, and National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center , T urning point therapeutics, Boston Pharmaceuticals. T ravel funding: Novartis, Pharmamar , ASCO, ESMO, Helsinn, Incyte, Ad Hoc Advisory Board: Helsinn, LOXO Oncology/Eli Lilly , R-Pharma US, INCYTE, QED pharma, MedImmune, Novartis, Signant Health. Dr Aung Naing reports grants from National Cancer Institute, grants from EMD Serono, grants from MedImmune, grants, non-financial support from ARMO BioSciences, grants from Karyopharm Therapeutics, grants from Incyte, grants, personal fees from Novartis, grants from Regeneron, grants from Merck, grants from Bristol-Myers Squibb, grants from Pfizer , grants, personal fees from CytomX Therapeutics, grants from Neon Therapeutics, grants from Calithera Biosciences, grants from T opAlliance Biosciences, grants from Eli Lilly , grants, personal fees from Kymab, grants from PsiOxus, grants from Arcus Biosciences, grants from NeoImmuneT ech, grants from ImmuneOncia, grants from Surface Oncology , grants, personal fees from Genome & Company , grants from OncoSec KEYNOTE-695, grants from STCube Pharmaceuticals, outside the submitted work; and Spouse • Research funding: Immune Deficiency Foundation, Jeffrey Modell Foundation and chao physician-scientist, and Baxalta. • Advisory board: T akeda, CSL, Behring, Horizon, and Pharming. Dr Filip Janku reports grants from Agios, grants, personal fees from Asana, grants from Astellas, grants from Astex, grants from Bayer , grants from Bicara, grants from BioMed V alley Discoveries, grants from Bioxcel, grants from Bristol-Myers Squibb, grants, personal fees from Deciphera, grants from FujiFilm Pharma, grants from Genentech, personal fees from Ideaya, grants from JS Innopharm, grants from Lilly , grants from Merck, grants, personal fees from Novartis, grants from Novellus, grants from Plexxikon, grants from Proximagen, grants from Sanofi, grants, personal fees from Sotio, grants from SpringBank Pharmaceuticals, grants from SQZ Biotechnologies, grants, personal fees from Synlogic, grants from Synthorx, grants from Symphogen, personal fees from Bausch Health, personal fees, Ownership Interests from Cardiff Oncology , personal fees from Guardant Health, personal fees from IFM Therapeutics, personal fees from Immunomet, personal fees from Illumina, personal fees Publisher Copyright: © 2021 Piha-Paul et al.
PY - 2021
Y1 - 2021
N2 - Background: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the development of resistance to monotherapy is an issue. The anti-angiogenic properties of pazopanib could overcome crizotinib drug resistance. Additionally, the anti-angiogenic properties of crizotinib could augment the clinical efficacy of pazopanib. Methods: We evaluated the safety and responses in patients with advanced solid tumors treated with crizotinib and pazopanib. Results: Eighty-two patients (median age 53 years, range 18–78 years) were enrolled. The median number of prior systemic therapies was 3 (range, 0–8). We were able to dose escalate to dose level 8 (crizotinib 250 mg twice daily and pazopanib 800 mg daily) with no MTD identified. Grade 3 or 4 toxicities were seen in 32% of patients with the highest prevalence being fatigue (n=9, 11%), diarrhea (n=6, 7%), vomiting (n=3, 4%), anemia (n=2, 2%) and ALT increased (n=2, 2%). Of the 82 patients, 61 (74%) had measurable disease by RECISTv1.1 and reached first restaging (6 weeks). Partial response (PR) was observed in 6/61 (10%) patients, and stable disease (SD) lasting ≥6 months was observed in 10/61 patients (16%) (total = 16/61 (26%) of patients with SD ≥6 months/PR). Conclusion: Dose level 6 (crizotinib 200 mg twice daily and pazopanib 600 mg daily) was the most tolerable dosing of the combination and can be used in future studies. We also observed moderate clinical activity in patients with advanced solid tumors that had received numerous prior therapies.
AB - Background: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the development of resistance to monotherapy is an issue. The anti-angiogenic properties of pazopanib could overcome crizotinib drug resistance. Additionally, the anti-angiogenic properties of crizotinib could augment the clinical efficacy of pazopanib. Methods: We evaluated the safety and responses in patients with advanced solid tumors treated with crizotinib and pazopanib. Results: Eighty-two patients (median age 53 years, range 18–78 years) were enrolled. The median number of prior systemic therapies was 3 (range, 0–8). We were able to dose escalate to dose level 8 (crizotinib 250 mg twice daily and pazopanib 800 mg daily) with no MTD identified. Grade 3 or 4 toxicities were seen in 32% of patients with the highest prevalence being fatigue (n=9, 11%), diarrhea (n=6, 7%), vomiting (n=3, 4%), anemia (n=2, 2%) and ALT increased (n=2, 2%). Of the 82 patients, 61 (74%) had measurable disease by RECISTv1.1 and reached first restaging (6 weeks). Partial response (PR) was observed in 6/61 (10%) patients, and stable disease (SD) lasting ≥6 months was observed in 10/61 patients (16%) (total = 16/61 (26%) of patients with SD ≥6 months/PR). Conclusion: Dose level 6 (crizotinib 200 mg twice daily and pazopanib 600 mg daily) was the most tolerable dosing of the combination and can be used in future studies. We also observed moderate clinical activity in patients with advanced solid tumors that had received numerous prior therapies.
KW - ALK/ROS1
KW - Crizotinib
KW - MET
KW - Pazopanib
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=85106160744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106160744&partnerID=8YFLogxK
U2 - 10.2147/OTT.S291801
DO - 10.2147/OTT.S291801
M3 - Article
C2 - 33994796
AN - SCOPUS:85106160744
SN - 1178-6930
VL - 14
SP - 3037
EP - 3049
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
ER -